Vicore Pharma (Buy, TP: SEK86.00) - Failed ATTRACT-3 trial undramatic
Vicore recently presented top-line data from its phase III ATTRACT-3 study in Covid-19. The study did not meet its primary or secondary endpoints, and further development of C21 in Covid-19 will be discontinued. However, the indication accounted for only 5% of our valuation. Looking ahead, top-line data from the important phase II study in IPF is expected to be presented in Q4 and remains a major potential catalyst for the shares, in our view. We reiterate our BUY but have lowered our target price to SEK86 (91).Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.